JP2021529834A5 - - Google Patents

Info

Publication number
JP2021529834A5
JP2021529834A5 JP2021522935A JP2021522935A JP2021529834A5 JP 2021529834 A5 JP2021529834 A5 JP 2021529834A5 JP 2021522935 A JP2021522935 A JP 2021522935A JP 2021522935 A JP2021522935 A JP 2021522935A JP 2021529834 A5 JP2021529834 A5 JP 2021529834A5
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
substituted
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529834A (ja
JP7482122B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040418 external-priority patent/WO2020010155A1/en
Publication of JP2021529834A publication Critical patent/JP2021529834A/ja
Publication of JP2021529834A5 publication Critical patent/JP2021529834A5/ja
Priority to JP2024072451A priority Critical patent/JP2024102170A/ja
Application granted granted Critical
Publication of JP7482122B2 publication Critical patent/JP7482122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522935A 2018-07-03 2019-07-02 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 Active JP7482122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024072451A JP2024102170A (ja) 2018-07-03 2024-04-26 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693878P 2018-07-03 2018-07-03
US62/693,878 2018-07-03
US201962861078P 2019-06-13 2019-06-13
US62/861,078 2019-06-13
PCT/US2019/040418 WO2020010155A1 (en) 2018-07-03 2019-07-02 Compounds and compositions for treating conditions associated with sting activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024072451A Division JP2024102170A (ja) 2018-07-03 2024-04-26 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Publications (3)

Publication Number Publication Date
JP2021529834A JP2021529834A (ja) 2021-11-04
JP2021529834A5 true JP2021529834A5 (enExample) 2022-07-11
JP7482122B2 JP7482122B2 (ja) 2024-05-13

Family

ID=67441663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522935A Active JP7482122B2 (ja) 2018-07-03 2019-07-02 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2024072451A Pending JP2024102170A (ja) 2018-07-03 2024-04-26 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024072451A Pending JP2024102170A (ja) 2018-07-03 2024-04-26 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Country Status (6)

Country Link
US (1) US20210236466A1 (enExample)
EP (1) EP3818044A1 (enExample)
JP (2) JP7482122B2 (enExample)
CN (1) CN112823151B (enExample)
MA (1) MA53096A (enExample)
WO (1) WO2020010155A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120004785A (zh) 2018-07-03 2025-05-16 诺华制药股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
JP2022507697A (ja) * 2018-11-19 2022-01-18 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2022517797A (ja) * 2019-01-17 2022-03-10 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TW202043198A (zh) * 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2020252240A1 (en) * 2019-06-14 2020-12-17 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114761804A (zh) 2019-06-21 2022-07-15 艾福姆德尤股份有限公司 治疗癌症的方法
CN115867278B (zh) * 2020-04-10 2025-02-28 Ab科学有限公司 马赛替尼用于治疗covid-19的用途
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024500874A (ja) 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
EP4267129A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
US20240060982A1 (en) * 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
EP4267128A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
EP4274824A1 (en) * 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
CN116789641A (zh) * 2022-03-17 2023-09-22 中国科学院上海药物研究所 二氢异喹啉类化合物及其医药用途
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN115960047B (zh) * 2023-01-10 2025-04-15 中国药科大学 一种3-苯基-1h-吡唑类化合物及其用途
WO2025111251A1 (en) * 2023-11-20 2025-05-30 Exelixis, Inc. Compounds that inhibit polo-like kinase 4

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3563985A (en) * 1967-12-15 1971-02-16 Fmc Corp Process for preparing certain acylaminoisothiazoles
US4230713A (en) * 1979-01-19 1980-10-28 Ici Americas Inc. Heterocyclic tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene urea and phenyl esters of tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene carbamic acid compounds
DE3332270A1 (de) * 1983-09-07 1985-03-21 Bayer Ag, 5090 Leverkusen Herbizide mittel enthaltend metribuzin in kombination mit 1,4-disubstituierten pyrazol-derivaten
US5849769A (en) * 1994-08-24 1998-12-15 Medivir Ab N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
EP1019394A1 (en) * 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
PT1056725E (pt) * 1997-12-22 2006-09-29 Bayer Pharmaceuticals Corp Inibicao da raf-quinase usando ureias heterociclicas substituidas com arilo e heteroarilo
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
BR0213562A (pt) * 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP2385041B1 (en) * 2003-05-01 2013-09-18 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP2005104968A (ja) * 2003-09-12 2005-04-21 Sumitomo Chemical Co Ltd フェニルピラゾール化合物及びその用途
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
WO2006070198A1 (en) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EP1801098A1 (en) * 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
US8497285B2 (en) 2010-12-03 2013-07-30 The Trustees Of The University Of Pennsylvania Therapy of autoimmune colitis using a TIP60 inhibitor
PT2935227T (pt) * 2012-12-21 2017-12-06 Chemocentryx Inc Amidas diazol como antagonistas do recetor ccr1
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2015039334A1 (en) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CA2927009C (en) 2013-10-21 2019-04-23 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
JP2019510802A (ja) * 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
CN106986860A (zh) * 2017-05-19 2017-07-28 南京大学 一类含酰胺键的吡唑类抗肿瘤化合物的设计、合成
CN107417478B (zh) * 2017-06-05 2020-05-05 南京师范大学 一种催化氧化羰基化合成不对称二取代脲的方法
WO2018234807A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
EP3790500B1 (en) * 2018-05-10 2022-07-06 Koninklijke Philips N.V. Methods and systems for adjusting behavior of oral care device based on status of oral cavity

Similar Documents

Publication Publication Date Title
JP2021529834A5 (enExample)
JP2021529833A5 (enExample)
JP2022507697A5 (enExample)
JP2023509421A5 (enExample)
JP6839772B2 (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP6839761B2 (ja) 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP2022517797A5 (enExample)
JP7461741B2 (ja) 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JP6779299B2 (ja) 抗ｐｄ−ｌ１抗体およびその使用
JP7046973B2 (ja) 抗ｏｘ４０抗体およびその使用
WO2017016497A1 (en) Anti-pd-1 antibodies and uses thereof
JP2020182492A (ja) 抗ｃｄ１３７抗体
CN111094348B (zh) 双特异性抗pd1-抗tim3抗体
TW201920282A (zh) 抗egfr和pd-1的雙特異性抗體
WO2013082463A2 (en) Assays, antibodies, immunogens and compositions related to 5-fu
CN119136840A (zh) 喜树碱类衍生物及配体-药物偶联物
JP2019522624A (ja) 抗ｐｄ−ｌ１−抗ｔｉｍ−３二重特異性抗体
JP7059389B2 (ja) 抗ｐｄ－１抗体との組み合わせのための抗ｃｄ１３７抗体
JP7059388B2 (ja) 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体
TWI888704B (zh) 抗ｃｄ７３之抗體及其應用
WO2024204629A1 (ja) 抗ｃｄ２５抗体及び抗ｃｄ２５抗体－薬物コンジュゲート
RU2021126926A (ru) Антитела, которые связывают опухолевую ткань, для диагностики и лечения
NZ741686B2 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
NZ741686A (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers